Your CAPRA score stratifies your prostate cancer into risk categories that predict the likelihood of recurrence, metastasis, and cancer-specific mortality following treatment. A score of 0 to 2 indicates low-risk disease, with an estimated 85% five-year recurrence-free survival rate. These patients are often candidates for active surveillance or definitive treatment with excellent long-term outcomes. A score of 3 to 5 indicates intermediate-risk disease, with five-year recurrence-free survival of approximately 50 to 70%, where multimodal treatment (surgery with possible adjuvant radiation, or radiation with androgen deprivation) is frequently considered. A score of 6 to 10 indicates high-risk disease, with five-year recurrence-free survival of approximately 20 to 35%, where aggressive multimodal therapy is typically recommended.

The CAPRA score increases by one point for each additional risk factor, making it intuitive to understand how individual variables contribute to overall risk. A higher proportion of positive biopsy cores, higher Gleason grade, or advanced T-stage each independently worsen the prognosis and are reflected in the composite score.

The CAPRA score is used at the time of prostate cancer diagnosis, after biopsy results and staging information are available. It is appropriate for risk stratification to guide shared decision-making about treatment options — active surveillance versus surgery versus radiation therapy versus combination approaches. It is recommended by the NCCN as one of several validated risk stratification tools.

The CAPRA score is also valuable in research for standardizing patient populations across clinical trials and in quality improvement programs for comparing outcomes across institutions. It predicts outcomes across all treatment modalities, making it useful regardless of the treatment path chosen. Some clinicians also use serial CAPRA scoring to assess how risk profiles change with updated biopsy or staging information.

The CAPRA score was developed and initially validated at UCSF using a predominantly surgical cohort. While it has since been validated in multiple international cohorts and across treatment modalities (radiation, active surveillance), its predictive accuracy may vary somewhat across different populations and healthcare settings.

The score uses Gleason grading, which has been partially supplanted by the Grade Group system (ISUP 2014). While the Gleason patterns (3, 4, 5) used in CAPRA remain valid, clinicians should be aware of the evolving pathological grading landscape. Additionally, the CAPRA score does not incorporate MRI findings (PI-RADS score), genomic classifier results (Decipher, Oncotype DX Prostate), or PSMA-PET staging, all of which provide important prognostic information in contemporary practice.

The CAPRA score provides a population-level probability estimate and cannot predict individual outcomes with certainty. Two patients with the same CAPRA score may have different outcomes based on factors not captured by the score, including overall health, surgical technique, radiation dose, and tumor molecular biology.